AGIO
Agios Pharmaceuticals, Inc.- Healthcare
- Biotechnology
- $2.01B market cap
Forecast run · Sep 14, 2026Upside rank 1348 of 3,136
Model Signal
ForecastQ Daily Probabilities
38.3%
41.0%
15.6%
Analyst Consensus
Recommendation2.24/5 Buy
Last price$33.60
Price target$42.67
Implied move+27.0%
Analysts29
ForecastQ Portfolios
AGIO is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.
Company Profile
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.